Osteogenesis Imperfecta Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Osteogenesis Imperfecta (OI)  is  a  genetic  disorder  characterized  by  bones  that  break  easily,  often  from  little  or  no apparent cause. This disease is caused by a defect, or flaw, in the gene that produces type 1 collagen, a protein used to create bone.  Symptoms  include  bone  deformities,  multiple  broken  bones,  loose  joints,  weak  teeth,  heart  defects and respiratory problems. Treatment includes bisphosphonates and surgery.

The Osteogenesis imperfecta – Drugs In Development research report provides a comprehensive overview on the therapeutics under development for Osteogenesis imperfecta, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Osteogenesis imperfecta and features dormant and discontinued projects.

Key Targets in the Osteogenesis Imperfecta Pipeline Drugs Market

The key targets in the Osteogenesis Imperfecta pipeline drugs market are Sclerostin, Collagen Type I, microRNA 29B, Glycogen Synthase Kinase 3 Beta, and Transforming Growth Factor Beta among others.

Osteogenesis Imperfecta Drugs Market, by Targets

Osteogenesis Imperfecta Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the Osteogenesis Imperfecta Pipeline Drugs Market

The key mechanisms of action in the Osteogenesis Imperfecta pipeline drugs market are Sclerostin Inhibitor, Glycogen Synthase Kinase 3 Beta Inhibitor, Transforming Growth Factor Beta 1 Inhibitor, Transforming Growth Factor Beta 2 Inhibitor, Transforming Growth Factor Beta 3 Inhibitor, and Prostaglandin E2 Receptor EP4 Subtype Agonist among others.

Osteogenesis Imperfecta Pipeline Drugs Market, by MoA

Osteogenesis Imperfecta Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

Osteogenesis Imperfecta Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Osteogenesis Imperfecta pipeline drugs market are Subcutaneous, Intravenous, Oral, Topical, and Parenteral.

Osteogenesis Imperfecta Pipeline Drugs Market Analysis, by RoA

Osteogenesis Imperfecta Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Osteogenesis Imperfecta Pipeline Drugs Market

The key molecule types in the Osteogenesis Imperfecta pipeline drugs market are Monoclonal Antibody, Small Molecule, Fusion Protein, Cell Therapy, Synthetic Peptide, and Aptamer among others.

Osteogenesis Imperfecta Pipeline Drugs Market, by Molecule Type

Osteogenesis Imperfecta Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free sample report

Major Companies in the Osteogenesis Imperfecta Pipeline Drugs Market

The major companies in the Osteogenesis Imperfecta pipeline drugs market are Amgen Inc, Bone Therapeutics SA, Castle  Creek  Biosciences  Inc, Genzyme Corp, Keros   Therapeutics   Inc, Mereo Biopharma  Group  Plc, Nano   Intelligent   Biomedical Engineering   Corp, and Novosteo,  Inc among others.

Osteogenesis Imperfecta Pipeline Drugs Market, by Major Companies

Osteogenesis Imperfecta Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Osteogenesis Imperfecta Pipeline Drugs Market Overview

Key Targets Sclerostin, Collagen Type I, microRNA 29B, Glycogen Synthase Kinase 3 Beta, and Transforming Growth Factor Beta
Key Mechanisms of action Sclerostin Inhibitor, Glycogen Synthase Kinase 3 Beta Inhibitor, Transforming Growth Factor Beta 1 Inhibitor, Transforming Growth Factor Beta 2 Inhibitor, Transforming Growth Factor Beta 3 Inhibitor, and Prostaglandin E2 Receptor EP4 Subtype Agonist
Key Routes of Administration Subcutaneous, Intravenous, Oral, Topical, and Parenteral
Key molecule types Monoclonal Antibody, Small Molecule, Fusion Protein, Cell Therapy, Synthetic Peptide, and Aptamer
Major companies Amgen Inc, Bone Therapeutics SA, Castle  Creek  Biosciences  Inc, Genzyme Corp, Keros   Therapeutics   Inc, Mereo Biopharma  Group  Plc, Nano   Intelligent   Biomedical Engineering   Corp, and Novosteo,  Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteogenesis Imperfecta
  • The pipeline guide reviews pipeline therapeutics for Osteogenesis Imperfecta by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteogenesis Imperfecta therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteogenesis Imperfecta therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Osteogenesis Imperfecta

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteogenesis Imperfecta
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteogenesis Imperfecta pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Amgen Inc
Aptacure Therapeutics Ltd
Beryl Therapeutics Inc
Bone Therapeutics SA
Boost Pharma ApS
Castle Creek Biosciences Inc
Genzyme Corp
Keros Therapeutics Inc
Mereo Biopharma Group Plc
Mesentech Inc
Nano Intelligent Biomedical Engineering Corp
Novosteo Inc
Sanofi

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Osteogenesis Imperfecta – Overview

Osteogenesis Imperfecta – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Osteogenesis Imperfecta – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Osteogenesis Imperfecta – Companies Involved in Therapeutics Development

Amgen Inc

Aptacure Therapeutics Ltd

Beryl Therapeutics Inc

Bone Therapeutics SA

Boost Pharma ApS

Castle Creek Biosciences Inc

Genzyme Corp

Keros Therapeutics Inc

Mereo Biopharma Group Plc

Mesentech Inc

Nano Intelligent Biomedical Engineering Corp

Novosteo Inc

Sanofi

Osteogenesis Imperfecta – Drug Profiles

ALLOB – Drug Profile

Product Description

Mechanism Of Action

History of Events

Apc-001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CCB-001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Cell Therapy for Osteogenesis Imperfecta – Drug Profile

Product Description

Mechanism Of Action

History of Events

denosumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

fresolimumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

HU-671 – Drug Profile

Product Description

Mechanism Of Action

KER-012 – Drug Profile

Product Description

Mechanism Of Action

History of Events

MES-1007 – Drug Profile

Product Description

Mechanism Of Action

NOV-004 – Drug Profile

Product Description

Mechanism Of Action

History of Events

romosozumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

SAR-439459 – Drug Profile

Product Description

Mechanism Of Action

setrusumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

Synthetic Peptide for Osteogenesis Imperfecta – Drug Profile

Product Description

Mechanism Of Action

Osteogenesis Imperfecta – Dormant Projects

Osteogenesis Imperfecta – Discontinued Products

Osteogenesis Imperfecta – Product Development Milestones

Featured News & Press Releases

Oct 01, 2021: Mereo BioPharma and Ultragenyx present data from the phase 2b ASTEROID study of UX143 (setrusumab) in Osteogenesis Imperfecta (OI) at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting

Sep 27, 2021: Ultragenyx announces UX143 (setrusumab) data presentations at upcoming American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting

Sep 24, 2020: Mereo BioPharma receives FDA Rare Pediatric Disease Designation for setrusumab for the treatment of osteogenesis imperfecta

Sep 11, 2020: Keros Therapeutics presents results from preclinical studies investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual Meeting

Feb 28, 2020: Mereo BioPharma announces positive feedback from type B end-of-phase 2 meeting with the FDA and outlines pivotal phase 3 pediatric study design for setrusumab in osteogenesis imperfecta

Jan 14, 2020: Mereo BioPharma announces additional positive data from phase 2b ASTEROID study of setrusumab in adults with osteogenesis imperfecta and provides update on regulatory progress

Nov 11, 2019: Mereo Biopharma’s Setrusumab demonstrates dose-dependent bone building and trend in fracture reduction in phase 2b ASTEROID study in adults with osteogenesis imperfecta

Oct 23, 2019: HKBU drug the first in Hong Kong to be granted orphan drug designation by the US FDA

Sep 04, 2019: Mereo BioPharma announces Setrusumab 6-Month Phase 2b Data in Osteogenesis Imperfecta selected for Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting

Jun 03, 2019: Mereo reports positive data of setrusumab in Phase IIb open label arm

Oct 15, 2018: Completion of patient enrolment in phase 2b study of BPS-804 for the treatment of osteogenesis imperfecta

Nov 13, 2017: Mereo Receives EMA PRIME Designation for BPS-804 to Treat Osteogenesis Imperfecta

May 04, 2017: Initiation of BPS-804 potentially pivotal Phase 2b study in patients with osteogenesis imperfecta, an orphan disease

Feb 20, 2017: Mereo BioPharma: BPS-804 accepted for EMA Adaptive Pathways programme

Jun 30, 2016: Mereo’s BPS-804 granted EU Orphan Drug status for Osteogenesis Imperfecta

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Osteogenesis Imperfecta, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Osteogenesis Imperfecta – Pipeline by Amgen Inc, 2022

Osteogenesis Imperfecta – Pipeline by Aptacure Therapeutics Ltd, 2022

Osteogenesis Imperfecta – Pipeline by Beryl Therapeutics Inc, 2022

Osteogenesis Imperfecta – Pipeline by Bone Therapeutics SA, 2022

Osteogenesis Imperfecta – Pipeline by Boost Pharma ApS, 2022

Osteogenesis Imperfecta – Pipeline by Castle Creek Biosciences Inc, 2022

Osteogenesis Imperfecta – Pipeline by Genzyme Corp, 2022

Osteogenesis Imperfecta – Pipeline by Keros Therapeutics Inc, 2022

Osteogenesis Imperfecta – Pipeline by Mereo Biopharma Group Plc, 2022

Osteogenesis Imperfecta – Pipeline by Mesentech Inc, 2022

Osteogenesis Imperfecta – Pipeline by Nano Intelligent Biomedical Engineering Corp, 2022

Osteogenesis Imperfecta – Pipeline by Novosteo Inc, 2022

Osteogenesis Imperfecta – Pipeline by Sanofi, 2022

Osteogenesis Imperfecta – Dormant Projects, 2022

Osteogenesis Imperfecta – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Osteogenesis Imperfecta, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Osteogenesis Imperfecta Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Osteogenesis Imperfecta Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Osteogenesis Imperfecta Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Osteogenesis Imperfecta Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.